Which patents cover Tysabri (natalizumab) and what are they for?
Tysabri is a branded form of natalizumab. The specific patent titles, claims, and assignees depend on the country (and sometimes the filing family), and the provided information doesn’t include those details. Patent coverage typically spans one or more of these categories: the active ingredient and manufacturing process, formulation/stability, and sometimes specific clinical-use or combination-use claims.
When do Tysabri patents expire (and does exclusivity last longer than patents)?
Patent expiry dates vary by jurisdiction because patent terms run from the priority date and can be adjusted for extensions, regulatory delays, or patent term adjustments granted by local regulators. Exclusivity can also extend beyond the last granted patent through mechanisms such as:
- Supplementary protection/extension systems (varies by country)
- Data or market exclusivity rules tied to drug approval (varies by country)
Because no jurisdiction or specific patent numbers were provided, exact expiry timing can’t be stated from the available information.
Can biosimilars or generics enter while Tysabri patents are still active?
For biologics like natalizumab, “generic” equivalents are generally not the same as small-molecule generics. Biosimilar approval depends on regulatory pathway requirements, but marketing can be blocked by active patent rights and exclusivity. In practice, biosimilar developers often seek approval while negotiating how patent disputes and exclusivity periods affect launch.
If you share the country (US, EU/UK, Canada, etc.) and whether you mean “regulatory approval date” or “first commercial launch,” I can narrow the answer.
What happens when a biosimilar challenges Tysabri-related patents?
In many markets, patent challenges can trigger litigation and stay/trigger mechanisms that delay biosimilar launch until patent status changes (for example, expiry, invalidation, or non-infringement findings). The details depend heavily on the legal framework in that jurisdiction.
How to look up Tysabri patent status correctly
To get an accurate list of “Tysabri patents” you typically need:
- The drug name and active ingredient (natalizumab) and manufacturer/brand owner
- The country or region’s patent office database (and sometimes the EMA/FDA-related exclusivity registry)
- Search using patent assignees, the drug name, the monoclonal antibody name, and relevant synonyms
Quick clarifying question
Which jurisdiction do you mean by “Tysabri patents” (United States, EU, UK, Canada, etc.), and are you looking for specific patent numbers/expiry dates or general exclusivity/patent landscape?